Calliditas Therapeutics rises as FDA grants priority review to kidney disease drug

Calliditas Therapeutics AB

18/08/2023 10:31

** U.S.-listed shares of Sweden-based drug developer
Calliditas Therapeutics AB  CALTX.ST   CALT.O  rise 5.2% to
$16.72 premarket   
    ** Co says the U.S. Food and Drug Administration (FDA) has
accepted the application for full approval of its drug to treat
a chronic kidney disease called IgA nephropathy (IgAN)     
     ** IgAN, also called Berger's disease, occurs when proteins
build up in the kidneys, damaging tissues and leaking blood and
protein into urine 
    ** The drug, Tarpeyo, is currently approved under
accelerated approval in adults with IgAN at risk of rapid
disease progression to reduce level of protein in their urine
    ** FDA is set to make its decision by 20 December, company
said    
    ** Up to last close, U.S.-listed shares of CALT down ~6.5%
YTD 

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))